ASCO Data Could Clarify Ocular Toxicity Concerns For ImmunoGen’s Mirvetuximab

Pivotal Trial Results And Pooled Safety Analysis Being Presented

 
• By Alaric DeArment
  
ImmunoGen is presenting data at ASCO on mirvetuximab soravtansine in platinum-resistant FRa-high ovarian cancer • Source: Shutterstock

More from ASCO

More from Conferences